A Study Of PF-06263507 In Patients With Advanced Solid Tumors

• Status: Terminated
• Trial end date: 2015-06-29
• Target enrollment: 0
• Participant gender: All

Summary

To assess the safety and tolerability at increasing dose levels of PF-06263507 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: PF-06263507

Criteria

Inclusion Criteria:

• Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy or for which no standard therapy is available.

• Performance Status of 0 or 1.

• Adequate bone marrow, kidney, liver, and heart function.

Exclusion Criteria:

• Brain metastases requiring steroids.

• Major surgery or anti-cancer therapy within 4 weeks of study treatment start.

• Active bacterial, fungal or viral infection.